What a ride to be leading this effort to solve T cell recognition - incredible opportunity and team, and 5 years to throw everything we have at it. Thanks Cancer Grand Challenges National Cancer Institute The Mark Foundation for Cancer Research for the award - and Koch Institute at MIT MIT Dept of BE Ragon Institute for the continual support

Lots of people in CS are (almost surely) GPT-ing their peer reviews arxiv.org/abs/2403.07183

Flow/CyTOF users and leaders: here is an interface that allows you to see exactly where a given cell on a biaxial plot is on a corresponding UMAP. More details:

Library-based single-cell analysis of CAR signaling reveals drivers of in vivo persistence biorxiv.org/cgi/content/sh… #biorxiv_immuno

Very proud of this work by Caleb Perez! Elegantly combining elements of CAR screening and single cell genomics to give insight into how CAR composition affects T cell functional state, with a lot to learn about how to design CARs and the diversity possible for T cell function

I am excited to share our Nature Communications paper describing the structure of #LAG3 bound to MHC-II. This project was carried out by Q&M et al at Moffitt Research and provides new insights into the mechanism by which LAG3 suppresses T cell activation. nature.com/articles/s4146…

My department (MIT Biological Engineering) is hiring at the Assistant Professor level! We are looking for someone in immunology/immunotherapy/immune engineering, broadly defined. be.mit.edu/about/open-fac…

Congratulations David Baker (University of Washington, member of #CancerGrandChallenges team MATCHMAKERS), who's won the 2024 Nobel Prize in Chemistry for his pioneering work building new kinds of proteins! 👏 More about MATCHMAKERS, funded by Cancer Research UK National Cancer Institute The Mark Foundation for Cancer Research 👉 cancergrandchallenges.org/matchmakers

Thrilled to announce Boltz-1, the first open-source and commercially available model to achieve AlphaFold3-level accuracy on biomolecular structure prediction! An exciting collaboration with Jeremy Wohlwend, Saro and an amazing team at MIT and Genesis Therapeutics. A thread!

We’re in Boston for the 1st annual meeting of the Cancer Grand Challenges Challenges MATCHMAKERS team! The team, which we sponsor with Cancer Research UK & National Cancer Institute, is creating tools to predict T cell antigen specificity, which could unlock more effective immunotherapies. cancergrandchallenges.org/challenges/act…

Deeper and noninvasive metabolic imaging powered by multimode fiber sources by Kunzan Liu, Tong Qiu, Honghao Cao. Awesome collaboration with Prof Linda Gay Griffith Fan Wang Roger Kamm science.org/doi/10.1126/sc… news.mit.edu/2024/noninvasi…

One year into our TCR-based challenge, I can say already that leading a #CancerGrandchallenges team may the most scientifically rewarding thing I have done. Amazing way to do impactful, international research on very hard problems!

Our Director, Discovery Research, Russell McConnell, will be at ASGCT to discuss preclinical data that supports the promise of our iGPS gene delivery system to develop #invivo therapeutics for congenital & infectious diseases. Learn more: keloniatx.com/kelonia-therap… #ASGCT2025

Welcome to the team!!

So excited for Kelonia to have made this milestone!

In vivo CAR-T cell therapy nature.com/articles/s4157… rdcu.be/eI7zH This new Review discusses how technological advances that remove the need for ex vivo manipulation and chemotherapeutic conditioning could enable wider application of CAR-T cell therapies

I came to MIT to study in 1983 to pursue a PhD in the then-emerging field of Biochemical Engineering. Having arrived in North America a political refugee from war-torn Lebanon eight years earlier, the academic rigor of MIT courses and professors challenged me at a whole new